硼替佐米在多发性骨髓瘤中的疗效与应用

The Effect and Application of Bortezomib in the Treatment of Multiple Myeloma

目的探讨硼替佐米在多发性骨髓瘤治疗中的应用价值。方法选取2014年3月-2016年5月收治的多发性骨髓瘤患者58例为研究对象,经随机数字表法分为观察组与对照组,每组29例,对照组采用常规化疗方案治疗,观察组在对照组基础上应用硼替佐米,观察两组治疗效果及不良反应。结果观察组治疗总有效率为86.21%,对照组为62.07%,差异有统计学意义(P<0.05);观察组患者恶心、呕吐、血小板减少、虚弱、腹泻等不良反应发生率高于对照组,差异有统计学意义(P<0.05)。两组均未出现严重不良反应,未见治疗相关死亡病例,所有不良反应经对症治疗后恢复。结论在多发性骨髓瘤治疗中应用硼替佐米,可显著增强疗效,缓解病情,但其可能增加不良反应发生率,需注意用药剂量调整及对症治疗。

Objective To explore the application value of bortezomib in the treatment of multiple myeloma. Methods 58 cases of patients with multiple myeloma treated in our hospital from March 2014 to May 2016 were selected as the research objects and were randomly divided into the observation group and the control group, 29 cases in each group. Patients in the control group were treated with conventional chemotherapy while patients in the observation group were treated with bortezomib based on the treatment in the control group. The adverse reactions and clinical effect of the patients in two groups were observed. Results The total effective rate in the observation group was 86.21%, which was higher than control group 62.07%, and the difference was statistically significant（P〈0.05）. The incidence of nausea, vomiting, thrombocytopenia, weakness, diarrhea and other adverse reactions in the observation group were higher than those in the control group, and the difference was statistically significant（P〈0.05）. There were no serious adverse reactions in two groups and no treatmentrelated deaths. All the adverse reactions were recovered after symptomatic treatment. Conclusion The use of bortezomib in the treatment of multiple myeloma can significantly improve the efficacy and ease the disease, but it may increase the incidence of adverse reactions. Attention should be paid to medication dosage adjustment and symptomatic treatment